Abstract
Syntheses of thirty 2,4,6-trichlorophenylhydrazine Schiff bases 1-30 were carried out and evaluated for their in vitro DPPH radical and super oxide anion scavenging activities. Compounds 1-30 have shown a varying degree of DPPH radical scavenging activity and their IC50 values range between 4.05-369.30 µM. The compounds 17, 28, 18, 14, 8, 15, 12, 2, 29, and 7 exhibited IC50 values ranging between 4.05 ± 0.06-24.42 ± 0.86 µM which are superior to standard n-propylgallate (IC50 = 30.12 ± 0.27 µM). Selected compounds have shown a varying degree of superoxide anion radical scavenger activity and their IC50 values range between 91.23-406.90 µM. The compounds 28 8, 17, 15, and 14, showed IC50 values between 91.23 ± 1.2-105.31 ± 2.29 µM which are superior to standard n-propylgallate (IC50 = 106.34 ± 1.6 µM).
Keywords: 2, 4, 6-Trichlorophenylhydrazine Schiff bases, DPPH radical, superoxide anion scavengers, trichlorophenylhydrazine, radical scavenging, propylgallate, antituberculosis, antifungal, rodenticides
Medicinal Chemistry
Title:2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers
Volume: 8 Issue: 3
Author(s): Khalid Mohammed Khan, Zarbad Shah, Viqar Uddin Ahmad, Momin Khan, Muhammad Taha, Fazal Rahim, Sajjad Ali, Nida Ambreen, Shahnaz Perveen, M. Iqbal Choudhary and Wolfgang Voelter
Affiliation:
Keywords: 2, 4, 6-Trichlorophenylhydrazine Schiff bases, DPPH radical, superoxide anion scavengers, trichlorophenylhydrazine, radical scavenging, propylgallate, antituberculosis, antifungal, rodenticides
Abstract: Syntheses of thirty 2,4,6-trichlorophenylhydrazine Schiff bases 1-30 were carried out and evaluated for their in vitro DPPH radical and super oxide anion scavenging activities. Compounds 1-30 have shown a varying degree of DPPH radical scavenging activity and their IC50 values range between 4.05-369.30 µM. The compounds 17, 28, 18, 14, 8, 15, 12, 2, 29, and 7 exhibited IC50 values ranging between 4.05 ± 0.06-24.42 ± 0.86 µM which are superior to standard n-propylgallate (IC50 = 30.12 ± 0.27 µM). Selected compounds have shown a varying degree of superoxide anion radical scavenger activity and their IC50 values range between 91.23-406.90 µM. The compounds 28 8, 17, 15, and 14, showed IC50 values between 91.23 ± 1.2-105.31 ± 2.29 µM which are superior to standard n-propylgallate (IC50 = 106.34 ± 1.6 µM).
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Shah Zarbad, Uddin Ahmad Viqar, Khan Momin, Taha Muhammad, Rahim Fazal, Ali Sajjad, Ambreen Nida, Perveen Shahnaz, Iqbal Choudhary M. and Voelter Wolfgang, 2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers, Medicinal Chemistry 2012; 8 (3) . https://dx.doi.org/10.2174/1573406411208030452
DOI https://dx.doi.org/10.2174/1573406411208030452 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptide5 Attenuates rtPA Related Brain Microvascular Endothelial Cells Reperfusion Injury via the Wnt/β-Catenin Signalling Pathway
Current Neurovascular Research Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer’s Disease
Current Alzheimer Research Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue:Drug-eluting Stents and Concomitant Treatment)
Cardiovascular & Hematological Disorders-Drug Targets Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies
Current Drug Abuse Reviews Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design